Curis, Inc. Elects Anne E. Borgman as Class I Director
October 14, 2022 at 04:02 pm EDT
Share
On October 12, 2022, the board of directors of Curis, Inc. elected Anne E. Borgman, M.D., to serve as a class I director until the 2024 Annual Meeting of Stockholders and thereafter until her successor is duly elected and qualified. Dr. Borgman will serve on the Nominating and Corporate Governance Committee, effective immediately, until her successor is duly appointed and qualified or until her earlier resignation or removal. Dr. Borgman will receive compensation for her board service as a non-employee director commensurate with the Company's previously-disclosed director compensation program, including a one-time nonqualified stock option under the Fourth Amended and Restated 2010 Stock Incentive Plan to purchase 25,000 shares of the company's common stock with an exercise price equal to the closing price of the company's common stock on the Nasdaq Global Market on the grant date.
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.